申请人:Furukawa Shuntaro
公开号:US08507504B2
公开(公告)日:2013-08-13
The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2′-methyl-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinolin]-7′-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.
本发明涉及一种制备3-(2,6-二氯苯基)-4-亚氨基-7-[(2′-甲基-2′,3′-二氢-1′H-螺[环丙烷-1,4′-异喹啉]-7′-基)氨基]-3,4-二氢嘧啶[4,5-d]嘧啶-2(1H)-酮化合物A的水合物或化合物A的药学上可接受的盐的过程,以及化合物A或化合物A的药学上可接受的盐的晶体形式,这些晶体形式在治疗各种癌症中作为激酶抑制剂特别是Weel激酶抑制剂中有用。